scholarly journals Induction of entosis in prostate cancer cells by nintedanib and its therapeutic implications

2019 ◽  
Author(s):  
Junjiang Liu ◽  
Lei Wang ◽  
Yunxia Zhang ◽  
Shoubin Li ◽  
Fuzhen Sun ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Prostate Cancer Cells ◽  
Therapeutic Implications

scholarly journals Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications

2019 ◽  
Vol 20 (16) ◽  
pp. 3881 ◽  
Author(s):  
Muhammet Oner ◽  
Eugene Lin ◽  
Mei-Chih Chen ◽  
Fu-Ning Hsu ◽  
G M Shazzad Hossain Prince ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Cancer Progression ◽  
Cyclin Dependent Kinase ◽  
Small Interfering Rnas ◽  
Prostate Cancer Cells ◽  
Cancer Cell Growth ◽  
Therapeutic Implications ◽  
The Central Nervous System ◽  
Near Future

Cyclin-dependent kinase 5 (CDK5) is a unique member of the cyclin-dependent kinase family. CDK5 is activated by binding with its regulatory proteins, mainly p35, and its activation is essential in the development of the central nervous system (CNS) and neurodegeneration. Recently, it has been reported that CDK5 plays important roles in regulating various biological and pathological processes, including cancer progression. Concerning prostate cancer, the androgen receptor (AR) is majorly involved in tumorigenesis, while CDK5 can phosphorylate AR and promotes the proliferation of prostate cancer cells. Clinical evidence has also shown that the level of CDK5 is associated with the progression of prostate cancer. Interestingly, inhibition of CDK5 prevents prostate cancer cell growth, while drug-triggered CDK5 hyperactivation leads to apoptosis. The blocking of CDK5 activity by its small interfering RNAs (siRNA) or Roscovitine, a pan-CDK inhibitor, reduces the cellular AR protein level and triggers the death of prostate cancer cells. Thus, CDK5 plays a crucial role in the growth of prostate cancer cells, and AR regulation is one of the important pathways. In this review paper, we summarize the significant studies on CDK5-mediated regulation of prostate cancer cells. We propose that the CDK5–p35 complex might be an outstanding candidate as a diagnostic marker and potential target for prostate cancer treatment in the near future.

scholarly journals Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications

2017 ◽  
Vol 10 (3) ◽  
pp. 357-366 ◽  
Author(s):  
Shalini S. Yadav ◽  
Jinyi Li ◽  
Jennifer A. Stockert ◽  
Bryan Herzog ◽  
James O'Connor ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Neuroendocrine Differentiation ◽  
Prostate Cancer Cells ◽  
Therapeutic Implications

279: Inhibition of Cyclooxygenase-2 Pathway Overcomes the Heat-Resistance in Prostate Cancer Cells

2007 ◽  
Vol 177 (4S) ◽  
pp. 93-93
Author(s):  
Makoto Sumitomo ◽  
Kenji Kuroda ◽  
Takako Asano ◽  
Akio Horiguchi ◽  
Keiichi Ito ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Heat Resistance ◽  
Cancer Cells ◽  
Cyclooxygenase 2 ◽  
Prostate Cancer Cells
Sign in / Sign up

Export Citation Format

Share Document